Amicus Therapeutics, Inc. (FOLD) Given Buy Rating at Chardan Capital
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report issued on Thursday. They currently have a $18.50 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $16.50. Chardan Capital’s target price would indicate a potential upside of 13.92% from the stock’s current price.
Other equities analysts have also issued reports about the company. J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday. Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday. Leerink Swann reaffirmed an “outperform” rating and set a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday. Bank of America Corporation upped their target price on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $18.25.
Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 16.24 on Thursday. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $16.60. The firm’s market capitalization is $2.67 billion. The company has a 50 day moving average of $13.93 and a 200-day moving average of $10.49.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. During the same period in the previous year, the firm earned ($0.40) earnings per share. Analysts predict that Amicus Therapeutics will post ($1.31) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/05/amicus-therapeutics-inc-fold-given-buy-rating-at-chardan-capital.html.
In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.40% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas grew its holdings in Amicus Therapeutics by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co bought a new position in Amicus Therapeutics in the 2nd quarter valued at $111,000. Tudor Investment Corp ET AL bought a new position in Amicus Therapeutics in the 2nd quarter valued at $124,000. Aperio Group LLC grew its stake in Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the period. Finally, Zacks Investment Management bought a new position in Amicus Therapeutics in the 2nd quarter valued at $145,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.